Evoltra Drug Improves Survival Rates in Leukemia
Posted on: Friday, 22 September 2006, 12:01 CDT
Bioenvision has presented results from an ongoing study of its drug Evoltra showing that the treatment improved survivial rates in children with relapsed/refractory acute leukemia.
Treating patients with multiple relapsed, or refractory leukemia is very difficult with only low response rates to existing treatment options and a poor prognosis with median survival of approximately nine to 10 weeks.
Evoltra managed to extend survival rates in some of the patients. Evoltra achieved a notable survival advantage, with a current median survival of 37.4 weeks in responding patients compared to 9.4 weeks in non-responding patients.
"The overall remission rate seen in this study is exceptional in such a difficult to treat group of patients who have failed other currently available treatments. Evoltra achieves durable responses with a notable survival advantage for the responders," commented Dr Pamela Kearns, Senior Lecturer in Pediatric Oncology, Bristol University.
"The majority of patients who received a transplant after responding to Evoltra are still alive, one is alive three years post transplant," commented Dr Rupert Handgretinger one of the transplant specialists in the study.
Evoltra was granted European marketing authorization by the European Commission in May 2006 and is available in all 25 member states of the European Union.
Source: Datamonitor
Related Articles
- Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
- Bristol-Myers Announces Updated Survival Data From Phase II Melanoma Studies
- Confirma and MEDRAD Partner to Advance Patient Care in the European Union
- Flamel Technologies Presents Results of a Clinical Trial of Its Medusa(R) Formulation of Interferon Alpha XL at the European Association for the Study of the Liver
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
- Pfizer and the European Foundation for the Study of Diabetes Announce a New Research Program Focused on Cardiovascular Risk in Patients With Diabetes
- The European Association for the Study of Diabetes
- New Data on Most Prescribed Hepatitis C Therapy Pegasys(R) Presented at European Association for the Study of the Liver (EASL) Conference
- Data Show Cyclosporine Inhalation Solution Improves Long-Term Survival in Lung-Transplant Patients
 |
 |
User Comments (0)
RSS Feeds